McKinsey’s analysis reveals that external innovation—which we define as assets that were externally sourced prior to launch—has been a reliable source of pipeline expansion, diversification, and value for biopharma companies. Since 2018, more than 70 percent of new molecular entity (NME) revenues have come from externally sourced products. Of these products, roughly 45 percent were sourced before launch. The dealmaking strategy has helped some companies outpace the industry’s anemic R&D productivity.
Read the full article: External Innovation: Biopharma Dealmaking to Boost R&D Productivity //
Source: https://www.mckinsey.com/industries/life-sciences/our-insights/external-innovation-biopharma-dealmaking-to-boost-r-and-d-productivity